The latest news, trends, analysis, interviews and podcasts from the global food and beverage industry

Meiji is set to launch a new line of functional yogurt products designed to address blood sugar management.

The 'Meiji Haemoglobin A1c Countermeasure Yogurt' and 'Meiji Haemoglobin A1c Countermeasure Yogurt Drink Type' will be available nationwide starting October 14 2025.

This product introduction marks a significant advancement in the functional food sector, as it features MI-2 lactic acid bacteria, which have been linked to lowering elevated haemoglobin A1c levels in healthy individuals.

The yogurt products come in convenient 112g portions and are positioned as a daily dietary supplement that can be easily incorporated into consumers' routines without the concern of added sugars. Each serving retails at 161 yen (approx. $1.05), making them accessible to a broad audience.

Haemoglobin A1c (HbA1c) is a critical biomarker for blood sugar control, providing insights into average blood glucose levels over a period of one to two months.

The launch of these products responds to an increasing consumer focus on health and wellness, particularly regarding diabetes management and overall metabolic health.

As the prevalence of diabetes and pre-diabetic conditions rises globally, Meiji aims to capture a segment of health-conscious consumers seeking functional foods that contribute to better health outcomes.

Research supporting the efficacy of MI-2 lactic acid bacteria indicates its potential role in managing HbA1c levels among individuals with high-normal ranges.

The company emphasises that while the products are designed to support blood sugar control, they are not classified as medicines and have not undergone government evaluation for their health claims.